US 7,612,199 B2
Polymorphic forms α, β, and γ of rifaximin
Guiseppe Glaudio Viscomi, Bologna (Italy); Manuela Campana, Bologna (Italy); Dario Braga, Bologna (Italy); Donatella Confortini, Bologna (Italy); Vicenzo Cannata, Bologna (Italy); Paolo Righi, Bologna (Italy); and Goffredo Rosini, Bologna (Italy)
Assigned to Alfa Wassermann, S.p.A., Bologna (Italy)
Filed on Jun. 04, 2009, as Appl. No. 12/478,638.
Application 12/478638 is a continuation of application No. 12/119600, filed on May 13, 2008.
Application 12/119600 is a continuation in part of application No. 11/873841, filed on Oct. 17, 2007.
Application 11/873841 is a continuation in part of application No. 11/135651, filed on May 24, 2005, abandoned.
Application 11/135651 is a continuation in part of application No. PCT/EP2004/012490, filed on Nov. 04, 2004.
Prior Publication US 2009/0234114 A1, Sep. 17, 2009
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 498/22 (2006.01)
U.S. Cl. 540—456 7 Claims
 
1. Rifaximin in polymorphic form α, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 7.4°; 19.7°; 21.0° and 22.1° 2-θ and wherein the rifaximin has a water content of less than 4.5%.